


Cardiovascular diseases (CVDs) have now become the leading cause of mortality in India. Hypertension is one of the key modifiable factors in addressing CVDs. RAAS blockers are at the center of Hypertension management, This CME aims at discussing about and defining the typical AT-RISK patient and the review of treatment approaches available for the management of AT-RISK patients under the light of recent evidences.

Sanofi, being a patient-centric diversified global healthcare organization, focused on patients' needs is facilitating this CME. It's our pleasure to invite you in this scientific program. We wish to be a partner in your endeavor towards improving patient health by enhancing the knowledge dissemination of evidence based approach in treating AT-RISK Patients

Date: 10-06-2018

Time: 10.30 a.m.

Venue: Hyatt Regency, Ashram Road, Ahmedabad



PARADOX CMEs

AGENDA

Topic	Speakers	Duration
Welcome	Sanofi	5 min
Moderator	Dr. Mustufa Rangwala	20 min
Introduction & Defining an AT-Risk Patient	Dr. Kaplesh Hansora	45 min
Role of ACE Inhibitors in management of AT-RISK Patients	Dr. Kamal Sharma	45 min
Q n A & Discussion	All Faculty	40 min
• Vote of Thanks	Sanofi	5 min

Followed by Lunch

Your valuable presence will be highly appreciated.



Dr. Mustufa Rangwala President - APA Dr. Ashvin Gadhavi Secretary - APA

